At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
AZD2171 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating AZD2171 and Fulvestrant for Advanced Breast Cancer. Completed, enrolled 75 participants across 16 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesAustralia, Brazil, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionDec 2008
Study CompletionApr 2016
TodayJul 2026
First PostedApr 2, 2007
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2008
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.3 years ago
Interventions
AZD2171drug
Oral tablet
Fulvestrantdrug
intramuscular injection